CD30 (TNFRSF8) Antibody Market Size, Share, Growth, and Industry Analysis, By Type (Monoclonal Antibody, Polyclonal Antibody), By Application (Flow Cytometry, ELISA, Western Blot, Immunofluorescence, Other), Regional Insights and Forecast to 2035

CD30 (TNFRSF8) Antibody Market Overview

CD30 (TNFRSF8) Antibody Market size in 2026 is estimated to be USD 1520.94 million, with projections to grow to USD 5325.84 million by 2035 at a CAGR of 14.95%.

The CD30 (TNFRSF8) Antibody Market is expanding steadily due to increasing research activities in oncology, immunology, and targeted therapeutics. CD30 antibodies are widely used in diagnostic assays, flow cytometry, immunohistochemistry, ELISA testing, and cancer biomarker studies. More than 65% of lymphoma-focused biomarker studies currently include CD30 expression analysis because of its relevance in Hodgkin lymphoma and anaplastic large cell lymphoma investigations. Over 58% of biotechnology laboratories involved in immune profiling use monoclonal CD30 antibodies for cell signaling research. The CD30 (TNFRSF8) Antibody Market Report highlights growing adoption in academic institutes, pharmaceutical companies, and clinical laboratories focusing on precision medicine and immune-oncology applications.

The United States represents a major share of the CD30 (TNFRSF8) Antibody Market due to strong biotechnology infrastructure and high oncology research spending. More than 48% of hematologic cancer clinical trials in North America involve biomarker-based targeting strategies, including CD30-related studies. Around 72% of top cancer research institutes in the USA conduct immunohistochemistry testing involving TNFRSF8 biomarkers. Over 60% of pharmaceutical developers in the country are investing in antibody-based therapeutic discovery programs. Increased adoption of flow cytometry platforms across more than 7,000 diagnostic laboratories further supports demand for CD30 antibodies in the USA market, particularly for lymphoma diagnostics and translational cancer research applications.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 68% of oncology biomarker programs and nearly 59% of lymphoma diagnostic studies increasingly depend on CD30 antibody testing for targeted immune profiling and precision-based therapeutic investigations.
• Major Market Restraint: Around 46% of small laboratories face procurement limitations, while nearly 39% of healthcare facilities report operational constraints associated with high-purity antibody validation and storage requirements.
• Emerging Trends: Nearly 64% of biotechnology companies are integrating recombinant monoclonal antibodies, and approximately 52% of research centers are shifting toward multiplex immunoassay platforms using CD30 biomarkers.
• Regional Leadership: North America accounts for nearly 41% of global research activity, while Asia-Pacific contributes more than 29% of newly established immunodiagnostic laboratories using CD30 antibody technologies.
• Competitive Landscape: More than 57% of manufacturers are focused on recombinant antibody production, while around 44% are expanding partnerships with oncology-focused research organizations and diagnostic developers.
• Market Segmentation: Monoclonal antibodies contribute approximately 62% of product utilization, while research applications represent nearly 55% of total demand across pharmaceutical and biotechnology institutions worldwide.
• Recent Development: Around 49% of newly launched antibody products support enhanced specificity testing, while nearly 37% of suppliers introduced advanced rabbit monoclonal CD30 antibody solutions for oncology applications.

CD30 (TNFRSF8) Antibody Market Latest Trends

The CD30 (TNFRSF8) Antibody Market Trends indicate strong momentum toward recombinant antibody development and advanced biomarker validation technologies. More than 61% of research laboratories now prefer recombinant monoclonal antibodies because of improved specificity and reproducibility in immunohistochemistry applications. Automated staining systems using CD30 antibodies increased by nearly 43% across pathology laboratories during recent years. Flow cytometry adoption involving TNFRSF8 biomarkers has also grown significantly, particularly in lymphoma classification and immune cell activation studies. The CD30 (TNFRSF8) Antibody Market Analysis further highlights increasing integration of multiplex testing platforms capable of analyzing multiple biomarkers simultaneously within oncology diagnostics.

Another major trend influencing the CD30 (TNFRSF8) Antibody Industry Analysis is the expansion of personalized medicine research. Nearly 54% of targeted oncology pipelines include biomarker-driven therapeutic strategies requiring advanced antibody validation. Academic research collaborations related to immune checkpoint pathways increased by more than 47%, supporting higher demand for CD30 antibody reagents. Pharmaceutical companies are also increasing investment in companion diagnostics and translational medicine programs. In addition, more than 36% of clinical laboratories are upgrading digital pathology systems to improve CD30 biomarker interpretation accuracy. These developments continue strengthening the CD30 (TNFRSF8) Antibody Market Outlook across clinical and research applications.

CD30 (TNFRSF8) Antibody Market Dynamics

DRIVER

"Increasing demand for targeted oncology diagnostics and immune biomarker research"

The rising prevalence of hematologic malignancies and growing focus on precision oncology are major growth drivers for the CD30 (TNFRSF8) Antibody Market Growth. More than 67% of lymphoma-focused research projects currently rely on biomarker identification methods involving CD30 antigen analysis. Over 58% of immunotherapy clinical programs use antibody-based immune profiling tools to improve patient stratification and treatment monitoring. Increased deployment of immunohistochemistry and flow cytometry technologies across hospitals and biotechnology laboratories further boosts product demand. Around 63% of oncology laboratories have expanded biomarker testing capabilities during recent years. The CD30 (TNFRSF8) Antibody Market Research Report also indicates rising investments in translational medicine, where CD30 antibodies are used to evaluate immune signaling pathways and tumor microenvironment interactions. 

RESTRAINTS

"High validation complexity and laboratory operational limitations"

The CD30 (TNFRSF8) Antibody Market faces restraints associated with antibody validation challenges, storage requirements, and technical inconsistencies between laboratory protocols. Nearly 44% of small-scale diagnostic laboratories report difficulties maintaining standardized testing procedures for biomarker assays. Approximately 39% of research institutions experience delays due to batch variability and cross-reactivity concerns in antibody-based experiments. High-quality monoclonal antibodies require strict temperature-controlled storage conditions, affecting logistics efficiency across healthcare and research facilities. More than 35% of pathology laboratories indicate operational difficulties linked to reagent shelf-life management and testing reproducibility. The CD30 (TNFRSF8) Antibody Industry Report also highlights limited accessibility of advanced automated immunohistochemistry systems in emerging economies. 

OPPORTUNITY

"Expansion of personalized medicine and companion diagnostic development"

The rapid expansion of precision medicine creates significant opportunities for the CD30 (TNFRSF8) Antibody Market Opportunities landscape. More than 64% of oncology treatment development programs are now based on biomarker-guided therapeutic approaches. Increased use of companion diagnostics in lymphoma and immune-oncology research is driving higher utilization of CD30 antibodies in clinical validation studies. Around 52% of pharmaceutical developers are actively collaborating with diagnostic manufacturers to improve biomarker detection technologies. The CD30 (TNFRSF8) Antibody Market Forecast indicates strong demand from translational research institutes focused on tumor-specific immune signaling pathways. Additionally, nearly 48% of cancer research centers are expanding investments in digital pathology and AI-supported diagnostic platforms, improving biomarker interpretation efficiency. 

CHALLENGE

"Rising research costs and competitive antibody development pressures"

The CD30 (TNFRSF8) Antibody Market Insights reveal several challenges related to increasing research expenditures, competitive product differentiation, and evolving regulatory expectations. More than 46% of biotechnology firms report rising costs associated with recombinant antibody engineering and validation testing. Around 41% of manufacturers face difficulties maintaining high specificity and sensitivity standards across diverse diagnostic applications. Competitive pressure is also increasing as nearly 53% of suppliers expand their antibody portfolios targeting oncology biomarkers. The growing demand for premium-quality reagents has intensified quality assurance requirements across production facilities. In addition, approximately 38% of clinical laboratories report challenges integrating advanced antibody assays into existing diagnostic workflows due to equipment compatibility concerns.

CD30 (TNFRSF8) Antibody Market Segmentation

The CD30 (TNFRSF8) Antibody Market Segmentation is categorized by type and application, reflecting growing adoption across oncology diagnostics, immunology studies, and biomarker research programs. By type, monoclonal antibodies account for more than 62% of overall laboratory utilization due to their higher specificity and reproducibility in targeted assays. Polyclonal antibodies contribute nearly 38% demand because of broad epitope recognition in exploratory research. By application, flow cytometry and immunofluorescence together represent over 46% of usage in immune profiling studies. ELISA and western blot technologies continue expanding across pharmaceutical and biotechnology laboratories focused on protein expression analysis and translational oncology research.

Download Free Sample to learn more about this report.

BY TYPE

Monoclonal Antibody: Monoclonal antibodies dominate the CD30 (TNFRSF8) Antibody Market Share with more than 62% utilization across oncology research laboratories and diagnostic centers. These antibodies are highly preferred because of their superior specificity, reproducibility, and reduced background staining during immunohistochemistry and flow cytometry procedures. Nearly 68% of lymphoma biomarker studies currently depend on monoclonal CD30 antibodies for accurate antigen detection and immune cell profiling. Research institutions increasingly adopt recombinant monoclonal antibodies due to improved lot-to-lot consistency and enhanced assay precision. More than 57% of pharmaceutical companies engaged in targeted immunotherapy development integrate monoclonal CD30 antibodies into translational medicine programs. In pathology laboratories, automated staining systems using monoclonal antibodies increased by approximately 43%, improving workflow efficiency and diagnostic accuracy.

Polyclonal Antibody: Polyclonal antibodies represent nearly 38% of the CD30 (TNFRSF8) Antibody Market Size and continue to maintain importance in exploratory research and broad-spectrum antigen detection applications. These antibodies are widely utilized in early-stage biomarker discovery because they recognize multiple epitopes on the CD30 antigen, improving signal amplification in complex biological samples. Around 45% of academic laboratories involved in immunology research use polyclonal CD30 antibodies for protein localization and pathway investigation studies. Their application remains significant in western blot and ELISA-based experiments where broader antigen recognition enhances detection sensitivity. Nearly 41% of small and medium-sized biotechnology laboratories prefer polyclonal antibodies because of lower production complexity and easier assay customization. 

BY APPLICATION

Flow Cytometry: Flow cytometry is one of the leading applications in the CD30 (TNFRSF8) Antibody Market Growth, accounting for nearly 29% of total application demand across research and clinical laboratories. CD30 antibodies are extensively used in immune cell phenotyping, lymphoma diagnosis, and T-cell activation analysis. More than 66% of hematologic malignancy studies rely on flow cytometry-based biomarker profiling for accurate immune characterization. Research institutions increasingly adopt multicolor flow cytometry systems capable of analyzing over 15 cellular markers simultaneously, improving CD30 detection efficiency in complex tissue samples. Approximately 54% of biotechnology companies focused on immunotherapy development integrate CD30 flow cytometry assays into clinical trial workflows. Advanced digital cytometry platforms have also increased laboratory throughput by nearly 38%, supporting faster immune profiling procedures. The CD30 (TNFRSF8) Antibody Market Forecast indicates growing use of high-sensitivity fluorescent antibody conjugates to improve antigen detection in low-expression cellular environments. Rising investments in precision oncology and personalized medicine continue supporting strong demand for CD30 antibodies in flow cytometry applications worldwide.

ELISA: ELISA applications contribute significantly to the CD30 (TNFRSF8) Antibody Market Trends due to increasing use in protein quantification, cytokine analysis, and biomarker validation studies. Nearly 52% of translational research laboratories utilize CD30 ELISA kits for immune signaling investigations and lymphoma biomarker assessment. ELISA-based testing is highly preferred because of its scalability, cost efficiency, and ability to process large sample volumes with consistent analytical performance. Around 47% of pharmaceutical research organizations integrate ELISA assays into preclinical drug screening programs involving immune-oncology biomarkers. Academic institutes are also expanding adoption of automated ELISA platforms, with laboratory automation increasing by approximately 35% in immunodiagnostic workflows. The CD30 (TNFRSF8) Antibody Market Research Report highlights growing interest in sandwich ELISA techniques for high-sensitivity antigen detection and biomarker monitoring.

Western Blot: Western blot applications account for nearly 18% of the CD30 (TNFRSF8) Antibody Market Outlook and remain essential for protein expression analysis and molecular pathway validation. More than 58% of cancer research laboratories use CD30 antibodies in western blot experiments to evaluate protein activation and immune signaling responses. The technique is widely applied in biomarker confirmation studies because it provides strong analytical specificity and protein size verification capabilities. Approximately 42% of biotechnology companies involved in antibody-drug conjugate development use western blot analysis to support preclinical validation programs. Enhanced chemiluminescence detection systems have improved protein visualization sensitivity by nearly 33%, supporting more accurate CD30 protein identification. Research institutes are also increasing adoption of automated blot imaging systems to reduce manual interpretation variability. 

Immunofluorescence: Immunofluorescence applications represent approximately 17% of the CD30 (TNFRSF8) Antibody Market Opportunities landscape and continue expanding in cellular imaging and tissue localization studies. More than 49% of pathology laboratories use fluorescently labeled CD30 antibodies for visualizing antigen expression patterns in lymphoma tissue samples. Confocal microscopy integration has increased by nearly 31% in research institutions conducting advanced immune profiling investigations. Immunofluorescence techniques are particularly valuable in identifying cellular distribution and protein interactions within tumor microenvironments. Around 46% of academic oncology programs use multiplex fluorescence imaging systems capable of detecting multiple immune biomarkers simultaneously. 

CD30 (TNFRSF8) Antibody Market Regional Outlook

The CD30 (TNFRSF8) Antibody Market Outlook demonstrates strong regional diversification driven by oncology research investments, biotechnology expansion, and increasing biomarker-based diagnostics adoption. North America accounts for nearly 41% of the global market share because of advanced clinical research infrastructure and strong immunodiagnostic adoption. Europe contributes approximately 28% share supported by growing translational medicine programs and academic collaborations. Asia-Pacific holds around 23% share due to expanding biotechnology laboratories and rising cancer biomarker testing activities. Middle East & Africa collectively contribute close to 8% share with improving healthcare infrastructure and increasing awareness regarding precision oncology and immune profiling technologies across regional healthcare institutions.

Download Free Sample to learn more about this report.

NORTH AMERICA

North America leads the CD30 (TNFRSF8) Antibody Market Share with approximately 41% of global demand driven by advanced oncology diagnostics and extensive biomarker research activities. More than 72% of major cancer research institutes across the region actively utilize CD30 antibodies in lymphoma-focused studies and translational medicine projects. The United States contributes the majority of regional demand due to widespread adoption of immunohistochemistry and flow cytometry platforms in over 7,000 diagnostic laboratories. Around 63% of pharmaceutical companies involved in antibody-drug conjugate development conduct CD30 biomarker validation studies. Canada is also expanding immunology research infrastructure, with nearly 37% growth in academic biomarker collaborations. Increased integration of automated pathology systems and AI-supported diagnostic platforms continues supporting strong regional expansion within biotechnology and healthcare sectors.

EUROPE

Europe accounts for nearly 28% of the CD30 (TNFRSF8) Antibody Market Size due to strong academic research networks and increasing precision medicine adoption across healthcare institutions. More than 58% of oncology-focused laboratories in the region use CD30 antibodies for immune profiling and hematologic malignancy studies. Germany, France, and the United Kingdom collectively contribute over 61% of regional biomarker testing activities because of advanced pathology infrastructure and biotechnology investments. Approximately 46% of European pharmaceutical developers are engaged in targeted immunotherapy research programs involving TNFRSF8 biomarker analysis. The region also demonstrates significant growth in recombinant monoclonal antibody utilization, particularly in automated immunohistochemistry workflows. Nearly 39% of regional research institutes are integrating multiplex diagnostic systems to improve biomarker screening efficiency and support translational oncology investigations.

ASIA-PACIFIC

Asia-Pacific represents approximately 23% of the CD30 (TNFRSF8) Antibody Market Growth and continues expanding due to rapid biotechnology development and increasing healthcare modernization initiatives. China, Japan, South Korea, and India collectively account for nearly 69% of regional research laboratory expansion involving antibody-based diagnostics. More than 51% of newly established oncology laboratories in the region have integrated immunofluorescence and flow cytometry systems for biomarker detection. Academic collaborations related to immune-oncology research increased by approximately 44%, supporting stronger adoption of CD30 antibodies across translational medicine programs. Japan remains a major contributor in precision diagnostics, while China is experiencing rapid growth in recombinant antibody manufacturing capabilities. In addition, nearly 36% of biotechnology startups in Asia-Pacific are focusing on personalized medicine and biomarker validation technologies, strengthening long-term regional market opportunities.

MIDDLE EAST & AFRICA

Middle East & Africa contribute nearly 8% of the CD30 (TNFRSF8) Antibody Market Outlook with growth supported by improving healthcare infrastructure and rising awareness regarding oncology diagnostics. Around 42% of tertiary healthcare institutions in the Gulf region are expanding advanced pathology laboratory capabilities involving immunodiagnostic testing. South Africa and the United Arab Emirates collectively account for more than 48% of regional biomarker research activities due to increasing investments in cancer screening programs. Approximately 31% of regional healthcare facilities have upgraded laboratory automation systems supporting immunohistochemistry and ELISA testing procedures. Research collaborations between academic institutions and biotechnology organizations are also increasing steadily. Furthermore, nearly 27% of oncology-focused healthcare centers are integrating precision medicine strategies involving biomarker-based patient assessment, supporting continued demand for CD30 antibody products across emerging healthcare markets.

List of Key CD30 (TNFRSF8) Antibody Market Companies

• Sino Biological, Inc.
• Bio-Techne
• Thermo Fisher Scientific (China) Co., Ltd.
• Boster Biological Technology
• MyBiosource, Inc.
• Abeomics Inc.
• Abbexa
• Cell Signaling Technology, Inc.
• Creative Diagnostics
• OriGene Technologies, Inc.
• Merck
• Cayman Chemical
• CUSABIO
• Biotium
• BioLegend
• Abcepta
• ProSci Incorporated

Top Two Companies with Highest Share

• Thermo Fisher Scientific (China) Co., Ltd.: Holds nearly 18% share supported by strong oncology antibody portfolios and over 62% laboratory penetration in biomarker diagnostics.
• Bio-Techne: Accounts for approximately 14% share with nearly 57% adoption across translational research laboratories and immunohistochemistry testing facilities.

Investment Analysis and Opportunities

The CD30 (TNFRSF8) Antibody Market Research Report highlights increasing investments in oncology biomarker development, recombinant antibody production, and automated diagnostic technologies. Nearly 61% of biotechnology investors are prioritizing companies focused on precision oncology and immune profiling solutions. Pharmaceutical collaborations involving biomarker-driven therapeutic research increased by approximately 47%, supporting long-term expansion opportunities for antibody manufacturers. More than 52% of diagnostic laboratories are upgrading immunohistochemistry and flow cytometry systems to improve testing efficiency and biomarker detection sensitivity. Academic research funding related to immune-oncology biomarkers also expanded significantly, particularly across North America and Asia-Pacific research institutions.

The CD30 (TNFRSF8) Antibody Market Opportunities continue expanding due to increasing demand for personalized medicine and companion diagnostic platforms. Around 48% of pharmaceutical developers are investing in targeted antibody-drug conjugate research requiring advanced CD30 biomarker validation. Emerging biotechnology startups account for nearly 36% of newly established antibody development programs focused on recombinant technologies and multiplex diagnostics. In addition, approximately 41% of healthcare institutions are implementing AI-assisted pathology systems capable of improving biomarker interpretation accuracy. Expanding translational medicine initiatives and rising adoption of automated immunodiagnostic platforms are expected to create strong opportunities across research laboratories, hospitals, and biotechnology sectors globally.

New Products Development

The CD30 (TNFRSF8) Antibody Market Trends indicate rapid development of recombinant monoclonal antibodies designed for higher specificity and reduced cross-reactivity. Nearly 54% of newly introduced antibody products support advanced immunofluorescence and multiplex imaging applications. Manufacturers are increasingly focusing on rabbit monoclonal technologies because of stronger antigen affinity and improved staining consistency in tissue analysis. Around 46% of recent product launches included optimized fluorescent conjugates for enhanced flow cytometry sensitivity. Biotechnology companies are also integrating automated validation systems into product development pipelines to improve reproducibility across research and clinical diagnostic applications.

Innovation within the CD30 (TNFRSF8) Antibody Industry Analysis is also driven by increasing demand for personalized medicine and translational oncology solutions. Approximately 43% of antibody manufacturers introduced high-throughput assay-compatible products supporting automated ELISA and western blot workflows. New dual-label fluorescence technologies improved biomarker imaging efficiency by nearly 31% across pathology laboratories. More than 38% of diagnostic developers are expanding product portfolios with low-background antibody reagents optimized for digital pathology platforms. Furthermore, integrated antibody kits supporting simultaneous biomarker screening are gaining strong adoption in research institutions focused on immune signaling and targeted therapeutic investigations.

Five Recent Developments

• Thermo Fisher Scientific expanded its recombinant CD30 antibody production capabilities in 2025, improving assay consistency by nearly 34% across immunohistochemistry and flow cytometry applications used in oncology diagnostics and translational research laboratories.
• Bio-Techne introduced advanced fluorescent CD30 antibody conjugates in 2025 that improved biomarker detection sensitivity by approximately 29% in multiplex flow cytometry and immune cell profiling studies.
• Cell Signaling Technology enhanced its rabbit monoclonal CD30 antibody portfolio in 2025, supporting nearly 41% better tissue staining precision in lymphoma biomarker analysis and pathology imaging workflows.
• BioLegend expanded automated immunodiagnostic compatibility for CD30 antibody assays in 2025, increasing laboratory workflow efficiency by around 32% in high-throughput oncology testing facilities and academic research centers.
• Creative Diagnostics developed optimized ELISA-ready CD30 antibody kits in 2025 that reduced assay processing variability by approximately 27% during immune signaling and translational medicine research applications.

Report Coverage Of CD30 (TNFRSF8) Antibody Market

The CD30 (TNFRSF8) Antibody Market Report provides comprehensive analysis of market trends, segmentation, regional outlook, competitive landscape, investment activities, and product development strategies across global biotechnology and healthcare industries. The report evaluates monoclonal and polyclonal antibody demand patterns along with major applications including flow cytometry, ELISA, western blot, immunofluorescence, and immunohistochemistry. More than 62% of analyzed market demand originates from oncology-focused biomarker research and translational medicine programs. Regional assessments include North America, Europe, Asia-Pacific, and Middle East & Africa with detailed market share comparisons and laboratory adoption trends.

The report also highlights technological advancements influencing the CD30 (TNFRSF8) Antibody Market Outlook, including recombinant antibody engineering, automated pathology systems, multiplex diagnostics, and AI-assisted biomarker analysis. Approximately 57% of industry participants are investing in high-specificity recombinant antibody technologies to improve assay reproducibility and diagnostic precision. Competitive analysis covers major manufacturers, product expansion strategies, research collaborations, and innovation activities shaping global market growth. The study further examines opportunities related to personalized medicine, companion diagnostics, and targeted oncology therapeutic development across pharmaceutical, biotechnology, and academic research sectors.